94
Views
1
CrossRef citations to date
0
Altmetric
Anticancer Original Research Papers

TPD7 inhibits the non-small cell lung cancer HCC827 cell growth by regulating EGFR signalling pathway

, , , , &
Pages 110-116 | Received 10 Jan 2021, Accepted 11 Jun 2021, Published online: 01 Jul 2021
 

Abstract

Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases, and is characterized by more insensitivity to chemotherapy and poor prognosis. Epidermal growth factor receptor (EGFR) has been confirmed as a tumorigenic driving factor of NSCLC. Taspine has been proved effective in the inhibition of malignant tumours. Here, we found TPD7, a novel taspine derivative, exerted most inhibitory effect on EGFR-dependent HCC827 cells and investigated the underling mechanism. In addition, TPD7 could block cell cycle at G0/G1 phase of HCC827 cells by regulating the expression of cyclin D1 and cyclin E. Furthermore, TPD7 induced HCC827 cell apoptosis by regulating the expression of BCL-2 family proteins. Further study revealed that TPD7 could down-regulate the phosphorylation of EGFR and downstream members. TPD7 might present a potential EGFR inhibitor in the treatment of NSCLC.

Disclosure statement

The authors declare no potential conflicts of interest.

Authors’ contributions

Zhang X performes the experiment. Zhang H performes the experiment. Qi G analyzes data. Gu X writes the paper. Zhao Y reads the paper. Zhang J designes the project.

Data availability statement

Our data are not deposited in publicly available repositories.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.